SSTR2 and neoplasm: The marked rise is more plausibly attributed to high post-treatment SSTR2 availability and favorable background activity (with normal spleen and liver SUVs in the expected ranges), as reflected by elevated tumor-to-liver and tumor-to-spleen ratios now detailed in Supplementary Tables S1, S2.